On Nov 08, major Wall Street analysts update their ratings for $McKesson (MCK.US)$, with price targets ranging from $612 to $688.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $612.
BofA Securities analyst Allen Lutz maintains with a buy rating, and adjusts the target price from $635 to $680.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $668.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $630 to $680.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $652 to $651.
Furthermore, according to the comprehensive report, the opinions of $McKesson (MCK.US)$'s main analysts recently are as follows:
The company's shares saw a 5% increase following a strong performance that addressed concerns regarding long-term target risks.
The firm highlighted that McKesson displayed robust performance across all segments with a particularly strong second-quarter showing in US Pharma. It was also noted that the guidance's midpoint suggests an encouraging acceleration in segment EBIT for fiscal year 25.
McKesson has addressed several issues and eliminated a number of significant uncertainties. The company, along with its peers, has consistently reported positive updates. Furthermore, large-cap healthcare stocks are currently rather undervalued and not widely held. There appears to be no compelling reason why the company would not revert to its recently higher valuation multiples.
Here are the latest investment ratings and price targets for $McKesson (MCK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
